CONMED Corp. Reaches New 1-Year High After Analyst Upgrade (CNMD)
CONMED Corp. (NASDAQ:CNMD) hit a new 52-week high during mid-day trading on Wednesday after Needham & Company raised their price target on the stock from $45.00 to $48.00, American Banking & Market News reports. Needham & Company currently has a buy rating on the stock. CONMED Corp. traded as high as $45.61 and last traded at $45.56, with a volume of 228,101 shares traded. The stock had previously closed at $44.60.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of CONMED Corp. in a research note on Monday, November 25th. They now have a $41.00 price target on the stock.
The stock’s 50-day moving average is $42.7 and its 200-day moving average is $37.23. The company has a market cap of $1.239 billion and a P/E ratio of 34.55.
CONMED Corporation (NASDAQ:CNMD) is a medical technology company/ The Company emphasizes on surgical devices and equipment for minimally invasive procedures and monitoring.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.